System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Anna Rita Bentivoglio is an expert in Neurology at Agostino Gemelli University Polyclinic (Italy). As of October 2026, ScienceLeadR ranks Anna Rita Bentivoglio in the top 1% of experts worldwide for Basal Ganglia Diseases and Parkinson Disease. Anna Rita Bentivoglio has authored 352 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 3 of them ongoing. SLR score: 1,068 (community average: 125). How the SLR is computed.

LeadR Profile

Anna Rita Bentivoglio Agostino Gemelli University Polyclinic Italy
1 068 ScienceLeadR Reputation 1068

Unlock

Register Login
Network Map

Neurology

Subspecialties: Psychiatry - Public Health - Neurosurgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1991 - 2026
Source: PubMed

Catholic University of the Sacred Heart

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 352

Citations

Citations: 20 940 1st author: 20 Last author: 68 Unique author: 2

Main journals

Mov Disord 47
Neurol Sci 24
Parkinsonism Relat Disord 21
J Neurol Neurosurg Psychiatry 20
J Neurol 15

Best Journals

N Engl J Med 3
Lancet 2
Science 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Different psychological and quality-of-life outcomes after subthalamic nucleus deep brain stimulation in Parkinson's disease patients: a prospective study.
PMID 42731544 — depression, quality of life, growth, parkinson disease, brain, tremor, movement disorders, deep brain stimulation, nervous system diseases, prospective studies, subthalamic nucleus, psychological well-being		Parkinsonism Relat Disord20260
Interrater and Intrarater Reliability of the TWSTRS-Delphi Motor Severity Scale for Cervical Dystonia.
PMID 42661413 — dystonia		Mov Disord Clin Pract20260
Is continuous dopaminergic delivery still a major goal to be achieved in the treatment of Parkinson's disease?
PMID 42427265 — parkinson disease, pharmaceutical preparations, dopamine, dopamine agents, therapeutics		J Parkinsons Dis20260
A Novel RORA Hinge-Region Variant in Adult IDDECA With Cerebellar Atrophy and Marked Response to Valproate.
PMID 42438296 — atrophy, phenotype, exome, nervous system diseases, intellectual disability, cerebellar ataxia		Eur J Neurol20260
Long-lasting concordance between imaging-guided and clinical-based STN-DBS programming enhances motor and axial outcomes in Parkinson's disease: A 3-year single-center study.
PMID 42411971 — parkinson disease, signs and symptoms, deep brain stimulation, software, speech, subthalamic nucleus		J Parkinsons Dis20260

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 5
N/A 3
Phase 2 1
Phase 2/Phase 3 1

By status:

Recruiting 3
Terminated 3
Completed 2
Active not recruiting 1
Unknown 1

By type:

Interventional 8
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 9

Main Topics

Cohort/Consortium Investigators 7

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson s Disease
2023-507132-21-00 — safety, parkinson disease, therapeutics		Phase 2/Phase 3Active not recruiting2021
A Phase III randomized placebo controlled parallel group double blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension
2025-523481-24-00 — supranuclear palsy, progressive, safety, double-blind method, paralysis		Phase 3Recruiting2026
A Phase 2 Study and Open Label Extension of NEU 411 in Companion Diagnostic Positive Participants With Early Parkinson s Disease
NCT06680830 — safety, parkinson disease, brain, leucine, small molecules		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS